Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vartumab ADC-MMAF
- Development stage
- Preclinical
- Lead developer
- Var2 Pharmaceuticals
- Modality
- scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Vartumab ADC-MMAF is an antibody-drug conjugate (ADC) designed to target oncofetal chondroitin sulfate (ofCS), a specific glycosaminoglycan modification found on proteoglycans in the tumor cell membrane and the malignant extracellular matrix. The drug consists of Vartumab—a single-chain variable fragment (scFv) fused to an albumin-binding domain (ABD) for extended plasma half-life—conjugated to the cytotoxic tubulin inhibitor monomethyl auristatin F (MMAF) via a cleavable valine-citrulline (vc) linker. Unlike its counterpart MMAE, the MMAF payload is highly polar and membrane-impermeable, which restricts its activity to the target-expressing cells upon internalization and prevents a bystander effect. Developed by VAR2 Pharmaceuticals, Vartumab ADC-MMAF has been utilized in preclinical research to demonstrate that while it possesses potent in vitro cytotoxicity, the lack of a bystander effect limits its in vivo efficacy against heterogeneous tumors compared to bystander-capable ADCs.
- Other names
- Vartumab-vc-MMAF
02
Targets
ofCS (Oncofetal chondroitin sulfate)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on Vartumab ADC-MMAF.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vartumab ADC-MMAF.